Valuation: Lyell Immunopharma, Inc.

Market Cap 268M 240M 221M 200M 375M 25.51B 381M 2.64B 1.05B 13.35B 1.01B 984M 42.28B P/E 2026 *
-1.51x
P/E 2027 * -1.42x
Enterprise Value 171M 153M 141M 128M 239M 16.27B 243M 1.68B 672M 8.51B 641M 628M 26.97B EV / Sales 2026 *
14,381x
EV / Sales 2027 * 24,220x
Free-Float
60.75%
Yield 2026 *
-
Yield 2027 * -
1 day+3.93%
1 week+21.11%
Current month+16.04%
1 month+17.96%
3 months-12.41%
6 months-44.85%
Current year-63.09%
1 week 9.05
Extreme 9.05
11.62
1 month 7.2
Extreme 7.195
11.62
Current year 7.2
Extreme 7.195
31.32
1 year 7.2
Extreme 7.195
45
3 years 7.2
Extreme 7.195
65.11
5 years 7.2
Extreme 7.195
309.9
10 years 7.2
Extreme 7.195
396.8
Manager TitleAgeSince
Chief Executive Officer 67 2022-12-14
Director of Finance/CFO 49 2026-03-08
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Chairman 65 2021-09-28
Director/Board Member 66 2020-04-30
Director/Board Member 66 2021-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Sell

Chief Technology Officer

-422 0.0017%
9/10/26 Other

Chief Technology Officer

47,500 0.1938%
9/10/26 Sell

Chief Technology Officer

-500 0.0020%
Change 5-day change 1-year change 3-year change Capi.($)
+3.93%+21.11%-31.53%-68.27% 268M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-1.51%-1.47%+25.89%+54.80% 45.99B
-0.77%-3.02%+17.74%+98.65% 42.45B
+0.86%+1.18%+227.32%+934.93% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.01%+5.06%+43.96%+140.06% 39.28B
Weighted average by Cap. -0.19%+3.14%+49.37%+160.69%

Financials

2026 *2027 *
Net sales 11.88K 10.64K 9.82K 8.88K 16.61K 1.13M 16.88K 117K 46.72K 592K 44.58K 43.64K 1.88M 9.88K 8.85K 8.16K 7.39K 13.82K 941K 14.04K 97.4K 38.86K 492K 37.08K 36.29K 1.56M
Net income -174M -156M -144M -130M -244M -16.61B -248M -1.72B -686M -8.69B -655M -641M -27.53B -238M -213M -197M -178M -333M -22.65B -338M -2.35B -936M -11.86B -893M -874M -37.55B
Net Debt -96.99M -86.87M -80.15M -72.53M -136M -9.24B -138M -956M -381M -4.83B -364M -356M -15.31B -28.54M -25.57M -23.59M -21.34M -39.91M -2.72B -40.56M -281M -112M -1.42B -107M -105M -4.51B
Projected Income Statement - Annual - Lyell Immunopharma, Inc.
Logo Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Employees
161
Date Price Change Volume
26-10-29 US$11.36 +3.93% 103,569
26-10-28 US$10.93 +8.00% 156,808
26-10-27 US$10.12 +8.70% 127,907
26-10-26 US$9.310 -0.85% 85,217
26-10-23 US$9.390 +0.11% 101,637
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Lyell Immunopharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.93USD
Average target price
37.88USD
Spread / Average Target
+246.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lyell Immunopharma, Inc.
  1. Stock Market
  2. Stocks
  3. LYEL Stock